Fig. 7: MCP disrupts Gal-3/RAB10 binding and inhibits macropinocytosis-mediated GSC survival.
From: Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells
a Macropinocytosis uptake assay using TMR-dextran in GSCs. Histograms represent the fold change of macropinocytosis activity in Ge518, Ge269, and Ge835 treated with MCP compared to their control (n = 3–5). Scale bar, 10 µm. b Effect of MCP on cell viability measured by CellTiter-Glo in GSCs (n = 3–6). c Effect of MCP on cell viability measured by CellTiter-Glo in GSCs (n = 3–5). d–f Mice were randomized and treated with either vehicle control (n = 5) or MCP (n = 5; 1% orally in the drinking water) after injection of Ge269, Ge518, and GBM10 cells, respectively. Data are represented as mean ± SEM (*p < 0.05, **p < 0.01, and ***p < 0.001), two-way ANOVA, Sidak’s adjusted p value. ns nonsignificant, Ctrl vehicle (H2O).
